Bristol Myers drops another CytomX program
Bristol Myers Squibb dropped another CTLA-4 program from its decade-long research collaboration with CytomX after the big pharma reviewed its portfolio.
CytomX announced the change …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
